Equities

Sumitomo Pharma Co Ltd

Sumitomo Pharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)609.00
  • Today's Change-2.00 / -0.33%
  • Shares traded2.22m
  • 1 Year change+26.88%
  • Beta0.6082
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform0
Hold5
Sell2
Strong Sell1

Share price forecast in JPY

The 7 analysts offering 12 month price targets for Sumitomo Pharma Co Ltd have a median target of 560.00, with a high estimate of 750.00 and a low estimate of 370.00. The median estimate represents a -8.05% decrease from the last price of 609.00.
High23.2%750.00
Med-8.0%560.00
Low-39.2%370.00

Dividends in JPY

Dividend information is not available for Sumitomo Pharma Co Ltd.
Div growth (TTM)-100.00%
More ▼

Earnings history & estimates in JPY

On Oct 30, 2024, Sumitomo Pharma Co Ltd reported 2nd quarter 2025 losses of -121.23 per share.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate-183.90%
Sumitomo Pharma Co Ltd reported annual 2024 losses of -792.79 per share on May 14, 2024.
Average growth rate-94.81%
More ▼

Revenue history & estimates in JPY

Sumitomo Dainippon Pharma Co., Ltd. had 2nd quarter 2025 revenues of 90.07m. This bettered the 88.03m consensus of the 5 analysts covering the company. This was 19.01% above the prior year's 2nd quarter results.
Average growth rate+4.24%
Sumitomo Dainippon Pharma Co., Ltd. had revenues for the full year 2024 of 314.56m. This was 43.38% below the prior year's results.
Average growth rate-7.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.